Resources Repository
-
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Mathematical Models | Cost-Effectiveness Analysis | Middle East & North Africa | Global | Chronic Disease/Risk | Health Outcomes | Calibration/Validation | Infectious Diseases | Health Systems | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Microsimulation | Cost-Effectiveness Analysis | State-Transition | Global | Chronic Disease/Risk | Test Performance | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2018Consequences of a Cigarette Price Increase in 13 Middle Income Countries
This study used extended cost-effectiveness analysis to examine the impact of a 50% increase in …
This study used extended cost-effectiveness analysis to examine the impact of a 50% increase in market prices of cigarettes on health, poverty, and financial protection for men in 13 middle income countries. A 50% increase in cigarette prices would lead to about 450 million years of life gained across the 13 countries from smoking cessation, with half of these in China. Across all countries, men in the bottom income group would gain 6.7 times more…
Mathematical Models | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Priority Setting/Ethics | Social Determinants | Policy/Regulation | Health/Medicine -
GuidelinesPublication 2011HPV Vaccine Introduction in LMIC's: Guidance on the Use of Cost-Effectiveness Models
This article is a literature review of HPV vaccination models suitable for low-income and middle-income …
This article is a literature review of HPV vaccination models suitable for low-income and middle-income country use to provide information about the feasibility of using such models in a developing country setting. The authors evaluated models in terms of their capacity, requirements, limitations and comparability. Their literature review identified six HPV vaccination models suitable for low-income and middle-income country use and representative of the literature in terms of provenance and model structure. Each model was…
Mathematical Models | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Calibration/Validation | Infectious Diseases | Health Systems | Clinical Care | Health/Medicine | Science/Technology -
ArticlePublication 2022Health and Financial Risk Protection Outcomes in Economic Evaluations
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution …
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution of health gains and financial risk protection. This information is typically presented in a joint display format. This article develops and applies an algebraic money-metric formulation that incorporates all disaggregated outcomes and finds that ranking of health interventions is sensitive to the decision maker’s aversion to inequality across income groups and that financial risk protection gains are most important to…
Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Priority Setting/Ethics | Social Determinants | Economics/Finance | Health/Medicine -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Costing Methods | Evidence Synthesis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2019Estimating the Total Incidence of Global Childhood Cancer: A Simulation-Based Analysis
This study describes the development of a microsimulation model to simulate childhood cancer incidence for …
This study describes the development of a microsimulation model to simulate childhood cancer incidence for 200 countries/territories, taking into account trends in population growth and urbanicity, geographical variation in cancer incidence, and health system barriers to access and referral that contribute to underdiagnosis. The model was calibrated to publicly available cancer registry data, and the total incidence of childhood cancer (diagnosed and undiagnosed) was estimated for each country in 2015 and projections made to 2030.…
Microsimulation | Global | Chronic Disease/Risk | Health Outcomes | Child/Nutrition | Health Systems -
ArticlePublication 2019Global Childhood Cancer Survival Estimates and Priority-Setting: A Simulation-Based Analysis
This modelling study provides estimates of global childhood cancer survival, accounting for the impact of …
This modelling study provides estimates of global childhood cancer survival, accounting for the impact of multiple factors that affect cancer outcomes in children. The authors developed a microsimulation model to simulate childhood cancer survival for 200 countries/territories, accounting for clinical and epidemiologic factors, including country-specific treatment variables, such as availability of chemotherapy, radiation, and surgery, and calibrated the model to empirical data from the CONCORD-2 and CONCORD-3 studies using an Approximate Bayesian Computation approach. The…
Microsimulation | Global | Chronic Disease/Risk | Priority Setting/Ethics | Health Outcomes | Child/Nutrition | Clinical Care -
ArticlePublication 2020Impact of Treatment and Imaging Modalities on 5-Year Net Survival of 11 Cancers in 200 Countries
This analysis describes the development of a microsimulation model of stage-specific cancer survival in 200 …
This analysis describes the development of a microsimulation model of stage-specific cancer survival in 200 countries/territories for 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix uteri, and prostate). The paper estimated current 5-year net survival for diagnosed cancers in each country and potential survival gains from increasing the availability of individual treatment and imaging modalities, and more comprehensive packages of scale-up. Global 5-year net survival for all 11 cancers (combined) is…
Microsimulation | Global | Chronic Disease/Risk | Priority Setting/Ethics | Health Outcomes | Calibration/Validation | Health Systems